Huntington's disease is a genetic neurodegenerative disorder that affects both motor and cognitive function and gradually reduces the independence and quality of life of those affected. One of the ...

In a study on treatments and outcomes in patients with Sydenham chorea (SC), corticosteroids were associated with faster resolution, while antibiotics, corticosteroids, and sodium valproate were ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA approved Ingrezza due to results from KINECT-HD, ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT ®-HD2 study demonstrating an established long-term safety ...

SAN DIEGO, Aug. 18, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA® (valbenazine) capsules for the ...

Credit: Getty Images. Valbenazine 40mg achieved greater placebo-adjusted improvement in chorea as early as week 2 and sustained greater efficacy through week 12 compared with placebo. Valbenazine ...

Prescription Drug User Fee Act (PDUFA) Target Action Date Set for August 20, 2023 SAN DIEGO, Dec. 22, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX), a leading ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo. The drug valbenazine statistically improves chorea, a ...

A case report indicates that valbenazine may be an effective therapy for chorea-ballism associated with tardive dyskinesia. Valbenazine has therapeutic potential to improve chorea-ballism associated ...

SAN DIEGO, Dec. 22, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that the U.S. Food and Drug ...